An antitumor composition, a medicine for preventing and / or treating a tumor, and use

Abstract

The present application belongs to the technical field of biological medicine, and particularly relates to an anti-tumor composition, a medicine for preventing and / or treating tumors and application. The anti-tumor composition provided by the present application comprises piceatannol and beta-carotene; the combined preparation of the piceatannol and the beta-carotene can inhibit the proliferation and growth of various tumor cells of breast cancer, liver cancer, gastric cancer, prostate cancer, lung cancer and colorectal cancer; taking breast cancer and colorectal cancer as examples, it is proved that the piceatannol and the beta-carotene can inhibit the growth and metastasis of tumors, and it is known that the piceatannol and the beta-carotene have application prospects in treating and preventing various cancers, which indicates that the composition of the present application can significantly inhibit the proliferation, growth and metastasis of tumors, and can be used for preparing a medicine for preventing and / or treating primary and metastatic tumors.

Description

Technical Field

[0001] This invention belongs to the field of biomedical technology, specifically relating to an anti-tumor composition, a drug for the prevention and / or treatment of tumors, and its application. Background Technology

[0002] Common cancers in humans include lung cancer, colorectal cancer, pancreatic cancer, cervical cancer, and breast cancer. Among these, breast cancer is a benign or malignant tumor caused by the abnormal division and proliferation of mammary epithelial cells. Globally, breast cancer ranks second in incidence, accounting for 11.6% of all cancers, with a mortality rate of 6.6%. Despite recent advances in the diagnosis and treatment of breast cancer, it remains a global health problem affecting millions. Common treatments include chemotherapy, surgery, radiotherapy, and hormone therapy. However, these treatments can cause adverse reactions and multidrug resistance, leading to complications. Due to the abundance and diversity of natural products, their multi-target mechanisms of action, and good safety profiles, there is an increasing demand for novel anticancer drugs derived from medicinal plants and natural products. Currently, there are no reports in existing technologies regarding the combined use of paclitaxel and beta-carotene for the prevention and treatment of tumors. Summary of the Invention

[0003] This invention provides an antitumor composition, a drug for the prevention and treatment of tumors, and its application. The antitumor composition of this invention includes paclitaxel and β-carotene, which can prevent and treat a variety of tumors.

[0004] To address the above problems, the present invention provides the following technical solution:

[0005] The present invention provides an antitumor composition comprising: paclitaxel and β-carotene.

[0006] Preferably, the mass ratio of paclitaxel to β-carotene in the composition is (10:1) to (1:10).

[0007] The present invention provides the use of the composition described in the above technical solution in the preparation of tumor prevention and / or treatment drugs and / or the preparation of immune enhancers.

[0008] Preferably, the tumor includes one or more of breast cancer, liver cancer, stomach cancer, prostate cancer, lung cancer, and colorectal cancer.

[0009] Preferably, the drug is any one of the following:

[0010] (1) Drugs that inhibit the growth of tumor cells;

[0011] (2) Drugs that reduce the frequency of metastatic tumors;

[0012] (3) Drugs that reduce the number of distant metastatic lesions in metastatic tumors;

[0013] (4) Drugs that increase the ratio of cytotoxic T cells in tumors and spleen;

[0014] (5) Drugs that activate T cells in tumors and spleen.

[0015] Preferably, the immune enhancer is any one of the following:

[0016] ①Immune enhancers that increase the ratio of cytotoxic T cells in tumors and spleen;

[0017] ②An immune enhancer that activates T cells in tumors and the spleen.

[0018] The present invention provides a medicament for the prevention and / or treatment of tumors, comprising the antitumor composition described above and pharmaceutically acceptable excipients.

[0019] Preferably, the dosage form of the drug includes one or more of oral dosage forms, injections, and suppositories.

[0020] The beneficial effects of this invention: This invention provides an antitumor composition comprising paclitaxel and β-carotene. This invention utilizes the combined formulation of paclitaxel and β-carotene to exhibit significant killing effects on various types of tumor cells, including breast cancer cells, liver cancer cells, gastric cancer cells, prostate cancer cells, lung cancer cells, and colorectal cancer cells. Example results show that monitoring tumor growth and distant organ metastasis in MMTV-PyVT transgenic mice with spontaneous breast cancer demonstrates that the combined formulation of paclitaxel and β-carotene can inhibit tumor cell growth, reduce the frequency of metastatic tumors, and decrease the number of distant metastatic lesions. Simultaneously, it can increase the ratio of cytotoxic T cells in tumors and the spleen, activate T cells, and enhance the ability of immune cells to kill tumor cells, showing promising application prospects for the prevention and treatment of various cancers. Furthermore, the examples also demonstrate that the combined formulation of paclitaxel and β-carotene can inhibit the growth of colorectal cancer cells. In this invention, the combined application of paclitaxel and β-carotene is more effective than either paclitaxel or β-carotene alone. The combined application of paclitaxel and β-carotene significantly enhances their ability to inhibit tumor growth and metastasis. The composition provided by this invention can significantly inhibit tumor proliferation, growth, and metastasis, and can be used to prepare drugs for tumor prevention and treatment. It is evident that the composition of this invention, containing both paclitaxel and β-carotene, consists of natural products with low toxicity, few side effects, and excellent preventive and therapeutic effects, providing a new research direction for the development of drugs for the prevention and treatment of tumors. Attached Figure Description

[0021] To more clearly illustrate the technical solutions in the embodiments of the present invention or the prior art, the accompanying drawings used in the embodiments will be briefly described below.

[0022] Figure 1 The combined formulation of paclitaxel and β-carotene exhibits inhibitory effects on the proliferation of various tumor cells;

[0023] Figure 2 The graph shows the effects of the combined formulation of paclitaxel and β-carotene on tumor growth and body weight in spontaneously breast cancer mice.

[0024] Figure 3 Figure showing the effect of the combined preparation of levofloxacin and β-carotene on lung metastases of breast cancer;

[0025] Figure 4 Figure showing the effect of the combined formulation of levofloxacin and β-carotene on the ratio and activity of T cells in the spleen and tumors of mice;

[0026] Figure 5 Figure showing the effects of paclitaxel or β-carotene alone on tumor growth and metastasis in spontaneous breast cancer mice;

[0027] Figure 6 This figure shows the changes in tumor growth in a PDX model mouse of colorectal cancer caused by the combined preparation of paclitaxel and β-carotene. Detailed Implementation

[0028] The present invention provides an antitumor composition comprising: paclitaxel and β-carotene.

[0029] This invention does not specifically limit the source of piceatannol and β-carotene; conventional commercially available products are sufficient. In this invention, piceatannol and β-carotene can be extracted from natural substances or synthesized artificially based on their chemical structural formulas. In this embodiment, the piceatannol (PIC) was purchased from Shanghai Bide Pharmaceutical Technology Co., Ltd., product number BD161462; the β-carotene was purchased from Shanghai Bide Pharmaceutical Technology Co., Ltd., product number BD116471.

[0030] The structural formula of piceatannol (PIC) described in this invention is shown in Formula 1. Piceatannol is a stilbene compound with antioxidant, antibacterial, anti-inflammatory, anti-aging, immunomodulatory, and anticancer biological activities. Piceatannol has relatively low toxicity to humans and is widely found in various fruits, traditional Chinese medicines, and plants.

[0031]

[0032] The structural formula of β-carotene described in this invention is shown in Formula 2. β-carotene is a natural pigment with a wide range of physiological functions, excellent anti-cancer effects, inhibits the growth of tumor cells and induces their apoptosis, and increases the level of reactive oxygen species in tumor cells.

[0033]

[0034] In this invention, the mass ratio of leucopicrin to β-carotene in the composition is preferably (10:1) to (1:10), more preferably (5:1) to (1:5), even more preferably (2:1) to (1:2), and more preferably 1:1.

[0035] This invention provides the application of the antitumor composition described above in the preparation of drugs for the prevention and / or treatment of tumors. The tumors described in this invention preferably include one or more of breast cancer, liver cancer, gastric cancer, prostate cancer, lung cancer, and colorectal cancer. The drugs are preferably any one of the following: (1) drugs that inhibit tumor cell growth; (2) drugs that reduce the frequency of metastatic tumors; (3) drugs that reduce the number of distant metastatic lesions; (4) drugs that increase the ratio of cytotoxic T cells in the tumor and spleen; (5) drugs that activate T cells in the tumor and spleen.

[0036] This invention provides the application of the antitumor composition described above in the preparation of immune enhancers.

[0037] The immune enhancer is any one of the following:

[0038] (1) Immunostimulants that increase the ratio of cytotoxic T cells in tumors and spleen; (2) Immunostimulants that activate T cells.

[0039] The present invention provides a medicament for the prevention and / or treatment of tumors, characterized in that it comprises the antitumor composition described in the above-mentioned technical solution and pharmaceutically acceptable excipients.

[0040] The dosage form of the drug includes one or more of the following: oral dosage form, injection, and suppository.

[0041] To further illustrate the present invention, the technical solutions provided by the present invention will be described in detail below with reference to the accompanying drawings and embodiments, but these should not be construed as limiting the scope of protection of the present invention.

[0042] Example 1

[0043] The combined preparation of paclitaxel and β-carotene inhibits the proliferation of multiple types of tumor cells.

[0044] The total concentration of the composition was 25 μg / mL. The preparation method of the drug was as follows: 5 mg of paclitaxel and 5 mg of β-carotene were dissolved in 1 mL of dimethyl sulfoxide to obtain a stock solution with a total concentration of 10 mg / mL. The stock solution was then diluted with cell culture medium to obtain a working concentration of 25 μg / mL. The drug was then used to treat the cells. The mass ratio of paclitaxel to β-carotene in the drug was 1:1.

[0045] 1. Experimental Methods:

[0046] (1) Detection of cell proliferation rate using CCK-8 assay

[0047] With 5×10 3 Tumor cells were seeded into 96-well plates at a density of cells / well and cultured for 16 hours in a 37°C incubator containing 5% CO2. The tumor cells included MDA-MB231 breast cancer cells, HepG2 liver cancer cells, HGC-27 gastric cancer cells, PC3 prostate cancer cells, A549 lung cancer cells, and HCT116 colorectal cancer cells. The specific treatment procedures for each cell type are as follows:

[0048] The treatment group consisted of cells treated with a drug concentration of 25 μg / mL in 96-well plates, with 3 replicates for each concentration.

[0049] The blank group consisted of the same volume of cell culture medium added to a 96-well plate, with 3 replicates.

[0050] The control group consisted of cells treated with 25 μg / mL dimethyl sulfoxide in 96-well plates, with three replicates for each concentration.

[0051] After 48 hours of drug treatment, 10 μL of CCK-8 reagent was added directly to the cell culture medium, and the cells were returned to the cell culture incubator for another 3 hours of incubation. The absorbance (OD) value at 450 nm was measured using a microplate reader. The cell viability (%) was calculated using the formula: Cell viability (%) = (OD value of treatment group – OD value of blank group) / (OD value of control group – OD value of blank group) × 100%.

[0052] 2. Experimental Results:

[0053] CCK-8 test results are as follows Figure 1As shown, the combined formulation of paclitaxel and β-carotene effectively inhibited the growth of various tumor cells, indicating that the combined formulation of paclitaxel and β-carotene has broad anti-tumor activity. The specific inhibition of cell viability against different cell types is as follows: MDA-MB231 (control group 100%, treatment group 20.3%), HepG2 (control group 100%, treatment group 23.5%), HGC-27 (control group 100%, treatment group 48.7%), PC3 (control group 100%, treatment group 76.4%), A549 (control group 100%, treatment group 37.5%), and HCT116 (control group 100%, treatment group 31%).

[0054] Example 2

[0055] 1. Effects of the combined preparation of paclitaxel and β-carotene on breast cancer tumor growth and metastasis.

[0056] Experimental methods

[0057] Twelve 7-week-old female MMTV-PyVT mice were used. The mice were housed in an environment with a relative humidity of 45%–55% and a controlled temperature of 20–25°C, using a 12-hour light / 12-hour dark cycle. The mice were randomly divided into two groups: a control group and a combination therapy group, with six mice in each group. The control group received 0.2 mL of sterile distilled water containing dimethyl sulfoxide (DMSO) per 20 g of mouse body weight via gavage, with a DMSO concentration of 0.05 mL / mL, once daily for eight weeks. The combination therapy group received a combination of paclitaxel and β-carotene aqueous solution via gavage. The aqueous solution was prepared by dissolving 200 mg of paclitaxel and 200 mg of β-carotene in 80 mL of sterile distilled water containing DMSO, with a DMSO concentration of 0.05 mL / mL. The combination therapy group received the drug once daily, with each dose consisting of 0.2 mL of the drug solution per 20 g of mouse body weight, for eight weeks.

[0058] Tumor size and body weight were measured weekly in both the control and combined treatment groups. After 8 weeks of drug administration, all mice were euthanized, and vital organs were collected for analysis. The differences between the two groups were assessed using a t-test. Statistical significance was defined as *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001.

[0059] 2 Experimental Results

[0060] (1) Measurement of tumor volume and body weight changes in mice in each experimental animal group

[0061] The formula for calculating the tumor inhibition rate is: Tumor inhibition rate (%) = (1 - tumor weight in the combined treatment group / tumor weight in the control group) * 100%.

[0062] Eight weeks after administration, the combined formulation of paclitaxel and β-carotene significantly inhibited the growth of breast cancer tumors in MMTV-PyVT transgenic mice, achieving an inhibition rate of 92.5%. Tumors in all mice were measured eight weeks after administration, and the results are shown below. Figure 2 From A, B, C, and D, we can see that the tumor volume of the control group (con) mice was 865.36 ± 246.39 mm. 3 The tumor weight was 3.20±0.82g; the tumor volume in mice treated with the combination of paclitaxel and β-carotene was 65.22±24.72mm. 3 The tumor weight was 0.42 ± 0.12 g; after 8 weeks of drug administration, the mice were dissected, and the tumor volumes of 6 mice in each group were as follows: Figure 2 As shown in Figure C, compared with the control group (con), the tumor growth of mice in the combination of paclitaxel and β-carotene (treat) was significantly inhibited (P < 0.001), while there was no significant difference in body weight. The body weight of mice in the control group (con) was 28.82 ± 1.68 g, and the body weight of mice in the combination of paclitaxel and β-carotene (treat) was 23.28 ± 0.54 g.

[0063] (2) HE staining to detect lung metastasis in MMTVPyVT breast cancer model mice

[0064] After euthanizing the mice, the lungs were removed, rinsed thoroughly, and fixed in 4 g / mL paraformaldehyde solution for 24 h. The lungs were then dehydrated, routinely embedded in paraffin, and sectioned. Hematoxylin-eosin staining was performed for 5 min, followed by dehydration and mounting with neutral resin.

[0065] HE staining results of mouse lung tissue are as follows Figure 3 As shown: Mice in the control group (con) had visible metastatic tumors in their lungs. After 8 weeks of combined intervention with piracetam and β-carotene, the size and number of metastatic tumors were significantly reduced. Compared to the average of 9.00±1.89 metastatic lesions in the control group, the combined treatment group (treat) had only 0.83±0.54 (P<0.01). The number of mice developing lung metastases was also significantly reduced (P<0.0001). All mice in the control group developed lung metastases, while only 33.3% of the mice in the combined treatment group developed metastases. This demonstrates that the combined piracetam and β-carotene treatment effectively inhibits lung metastases in breast cancer.

[0066] (3) Flow cytometry detection of changes in the proportion of T lymphocytes in mouse spleen

[0067] After euthanizing the mice, the spleen was aseptically removed and ground. The mixture was then filtered through a 200-mesh filter and centrifuged at 1500 rpm for 5 minutes. The supernatant was discarded, and 1 mL of erythrocyte lysis buffer was added to the resulting pellet. The pellet was incubated at room temperature for 2 minutes, and then 9 mL of physiological saline was added to terminate the lysis. After centrifugation at 1500 rpm for 5 minutes, the supernatant was discarded, and the resulting cell pellet was resuspended in PBS. The cell concentration in the resuspended pellet was adjusted to 0.5 × 10⁻⁶ cells / mL. 8 cells / mL ~ 1.0 × 10⁻⁶ 8 per mL.

[0068] Antibodies for CD3 (Catalog No. 100205, BioLegend), CD4 (Catalog No. 100509, BioLegend), CD8a (Catalog No. 100711, BioLegend), and CD69 (Catalog No. 104511, BioLegend) were added to 1 mL of flow cytometry buffer at the ratios recommended in the antibody instructions. The cells were incubated at 4°C in the dark for 30 min. After centrifugation at 1500 rpm for 5 min, the supernatant was discarded, and the cells were washed once with PBS. After centrifugation at 1500 rpm for 5 min, the supernatant was discarded, and 400 μL of PBS was added to each tube to resuspend the cells. Flow cytometry was used to detect changes in the proportion of T cells in the spleen.

[0069] (4) Flow cytometry detection of the proportion and activity of mouse tumor T lymphocytes

[0070] The Digestion Buffer consists of: 1640 medium, 0.1 mL / mL LFBS, 0.5 mg / mL collagenase D, and 0.1 mg / mL deoxyribonuclease I.

[0071] Tumor tissue was isolated and minced using curved scissors. Sufficient Digestion Buffer was added, and the mixture was shaken on a shaker for 1 hour. The digested tumor tissue was then ground on a 100-mesh sieve, passed through a 200-mesh sieve, and centrifuged at 1600 rpm for 5 minutes. The precipitate was resuspended in mouse lymphocyte separation medium, and the resuspended solution was topped with serum-free 1640 medium and centrifuged at 800g for 20 minutes. The intermediate layer containing tumor-associated immune cells was aspirated, centrifuged at 1600 rpm for 5 minutes, and the precipitate was resuspended in 1 mL of flow cytometry buffer. Cells were counted using a counting chamber. The resuspended solution was stained with antibody for 30 minutes, and after termination, it was passed through a 40 μM sieve for flow cytometry analysis.

[0072] The results are as follows Figure 4 As shown, the combined preparation of levofloxacin and β-carotene induced cytotoxic CD8+ in the spleen and tumors. + Increased proportion of T cells, CD8+ in the spleen +The proportion of T cells increased from 23.08±0.86% to 28.93±2.27% (P<0.05), and CD8+ cells were present in the tumor. + The proportion of T cells increased from 29.88±2.37% to 37.56±1.29% (P<0.05), and CD69... + CD8 + The proportion of T cells increased significantly from 10.34±3.97% to 41.70±9.76% (P<0.05), indicating that the combined preparation exerts its anti-tumor effect by activating T cells and enhancing the body's anti-tumor immune response.

[0073] 2. Compare the effects of the combination of paclitaxel and β-carotene versus paclitaxel or β-carotene alone on tumor growth and metastasis in mice.

[0074] Experimental methods:

[0075] Twenty-four 7-week-old female MMTV-PyVT mice were used. The mice were housed in an environment with a relative humidity of 45–55% and a controlled temperature of 20–25°C, using a 12-hour light / 12-hour dark cycle. The mice were randomly divided into four groups: a control group (con), a combination therapy group (combination), a picratecanthol group (PIC), and a β-carotene group, with six mice in each group. Treatments were as follows:

[0076] The control group mice were administered sterile distilled water containing dimethyl sulfoxide by gavage, with a dimethyl sulfoxide volume concentration of 0.05 mL / mL.

[0077] Mice in the combined formulation group were administered a combination of leucopicrin and β-carotene aqueous solution (referred to as leucopicrin-β-carotene aqueous solution) by gavage. The leucopicrin-β-carotene aqueous solution was prepared by dissolving 200 mg of leucopicrin and 200 mg of β-carotene in 80 mL of sterile dimethyl sulfoxide distilled water. The volume concentration of dimethyl sulfoxide in the sterile distilled water was 0.05 mL / mL.

[0078] The group receiving leucocele was given leucocele solution by gavage. The leucocele solution was prepared by dissolving 200 mg of leucocele in 40 mL of sterile dimethyl sulfoxide (DMSO) distilled water. The volume concentration of DMSO in the sterile distilled water was 0.05 mL / mL.

[0079] The β-carotene group was administered β-carotene solution by gavage. The β-carotene solution was prepared by dissolving 200 mg of β-carotene in 40 mL of sterile dimethyl sulfoxide distilled water. The volume concentration of dimethyl sulfoxide in the sterile distilled water was 0.05 mL / mL.

[0080] The four groups of mice were administered the drug once daily. The control group received 0.2 mL of sterile dimethyl sulfoxide (DMSO) distilled water per 20 g of mouse body weight via gavage, with a DMSO concentration of 0.05 mL / mL. The combination drug group, paclitaxel group, and β-carotene group received 0.2 mL of drug solution per 20 g of mouse body weight via gavage. Mice in each group were administered the drug for 8 consecutive weeks, with tumor size and body weight measured weekly. After the experiment, all mice were euthanized, and vital organs were collected for analysis. A t-test was used to assess differences between the two groups. *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001 were considered statistically significant.

[0081] The experimental results after 8 weeks of drug administration are shown in Figure 5 In a mouse model of breast cancer, compared with the control group (2618.50±934.28 mm), 3 Compared to tumors treated with β-carotene alone, the tumor size was 1214.80±620.56 mm. 3 It could not effectively inhibit tumor growth in mice, although oral administration of piperidine alone (818.55±284.29 mm) did not significantly reduce tumor growth. 3 It significantly inhibited the growth of breast cancer tumors in transgenic mice (P < 0.001). However, compared with the paclitaxel group, the β-carotene combination preparation (363.80 ± 85.00 mm) showed a smaller increase. 3 The combination therapy showed a more significant anti-tumor effect (P < 0.05). In the prevention and / or treatment of lung metastases from breast cancer, the average number of metastatic lesions in the control group, the combination therapy group, the paclitaxel group, and the β-carotene group were 18.20 ± 3.61, 2.40 ± 0.60 (P < 0.01), 5.80 ± 2.05 (P < 0.05), and 13.66 ± 3.83, respectively, indicating that the combination therapy of paclitaxel and β-carotene has a significant advantage in the effectiveness of preventing and / or treating breast cancer.

[0082] Example 3

[0083] Effects of a combination of paclitaxel and β-carotene on the growth of colorectal cancer

[0084] 1. Experimental Methods

[0085] Measurement of tumor volume and body weight changes in mice in different experimental animal groups

[0086] Ten male NOD-SCID mice, 7 weeks old, were used. The mice were housed in an environment with a relative humidity of 45%–55%, a controlled temperature of 20–25℃, and 12 hours of light / day followed by 12 hours of darkness. Fresh colorectal tumor tissue was obtained and cut into small pieces. The tumors were inoculated into the ventral region of the mice. Tumor formation was observed daily after inoculation. Once tumors were observed on the surface of the animals, the tumor-forming mice were randomly divided into two groups (n=5 per group): a control group (con) and a treatment group (treat). The control group received 0.2 mL of sterile dimethyl sulfoxide (DMSO) per 20 g of mouse body weight via gavage, with a DMSO concentration of 0.05 mL / mL, once daily for 8 weeks. Mice in the combined formulation group were administered an aqueous solution of paclitaxel and β-carotene by gavage. The aqueous solution was prepared by dissolving 200 mg of paclitaxel and 200 mg of β-carotene in 80 mL of water, with a dimethyl sulfoxide concentration of 0.05 mL / mL. The mice were administered the solution once daily at a volume of 0.2 mL of drug solution per 20 g of mouse body weight for 8 consecutive weeks. Tumor size and body weight were measured weekly in both the control and combined formulation groups.

[0087] 2. Experimental Results:

[0088] The combined formulation of paclitaxel and β-carotene significantly inhibited tumor growth in a colorectal cancer PDX model mouse, achieving an inhibition rate of 85.8%. The experimental results after 8 weeks of administration are as follows... Figure 6 As shown, Figure 6 The right figure shows the tumor volume of 5 mice after dissection in the control group and the combined treatment group after 8 weeks of drug administration. It can be seen that the tumor volume of the control group (1231.05±508.41 mm) was significantly larger than that of the combined treatment group. 3 Compared to the combination of paclitaxel and β-carotene (174.59±69.78 mm), the combined formulation group... 3 The tumor volume of mice was significantly reduced (P < 0.001), indicating that the combined preparation of paclitaxel and β-carotene can inhibit the growth of colorectal cancer.

[0089] In summary, the composition of paclitaxel and β-carotene provided by this invention has excellent quality and efficacy in inhibiting the growth of colorectal cancer and breast cancer.

[0090] Although the above embodiments have provided a detailed description of the present invention, they are only some embodiments of the present invention, and not all embodiments. People can obtain other embodiments based on these embodiments without creative effort, and these embodiments all fall within the protection scope of the present invention.

Claims

1. An antitumor composition, characterized by, Compositions comprising: piceatannol and beta-carotene; the mass ratio of piceatannol and beta-carotene in the composition is 1:

1.

2. Use of the composition of claim 1 in the preparation of a medicament for preventing and / or treating tumors; the tumors include one or more than two of breast cancer, liver cancer, gastric cancer, lung cancer and colorectal cancer.

3. Use according to claim 2, characterized in that, the medicament is any of the following: (1) a medicament for inhibiting tumor cell growth; (2) a medicament for reducing the frequency of metastatic tumors; (3) a medicament for reducing the number of metastatic tumor metastases; (4) a medicament for increasing the ratio of cytotoxic T cells in tumors and spleen; (5) a medicament for activating T cells in tumors and spleen.

4. Use of the composition of claim 1 in the preparation of an immune enhancer.

5. Use according to claim 4, characterized in that, the immune enhancer is any of the following: ① an immune enhancer for increasing the ratio of cytotoxic T cells in tumors and spleen; ② an immune enhancer for activating T cells in tumors and spleen.

6. A medicament for preventing and / or treating a tumor, characterized by, Compositions comprising the anti-tumor composition of claim 1 and pharmaceutically acceptable excipients.

7. The medicament according to claim 6, characterized in that, the dosage form of the medicament includes one or more of oral dosage form, injection and suppository.

Images